참고문헌
- Miller KB, Schenkein DP, Comenzo R, et al., Adjusteddose continuous-infusion cyclosporin A to prevent graftversus- host disease following allogeneic bone marrow transplantation. Ann Hematol. 1994; 68: 15-20. https://doi.org/10.1007/BF01695914
- Gondo H, Harde M, Taniguchi S, et al., Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease. Bone Marrow Transplant. 1993; 2: 437-441.
- Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem. 2001; 34(1): 9-16. https://doi.org/10.1016/S0009-9120(00)00175-2
- Abendroth D. Experience with therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004; 36(2 Suppl): 426S-429S. https://doi.org/10.1016/j.transproceed.2003.12.024
- Kasiske BL, Heim-Duthoy K, Rao KV, et al., The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation. 1988 Nov; 46(5): 716-722. https://doi.org/10.1097/00007890-198811000-00017
- Yee GC, Self SG, McGuire TR, et al., Serum cyclosporine concentration and risk of acute graft-versushost disease after allogeneic marrow transplantation. N Engl J Med. 1988; 319:65-70. https://doi.org/10.1056/NEJM198807143190201
- Parkman R. Cyclosporine: GVHD and beyond. N Engl J Med. 1988; 319: 110-111. https://doi.org/10.1056/NEJM198807143190209
- Przepiorka D, Shapiro S, Schwinghammer TL, et al., Cyclosporine and methylprednisolone after allogeneic marrow transplantation: Association between low cyclosporine concentration and risk of acute graft-versushost disease. Bone Marrow Transplant. 1991; 7: 461-465.
- Schmidt H, Ehninger G, Dopfer R, et al., Correlation between low CSA plasma concentration and severity of acute GvHD in bone marrow transplantation. Blut. 1988; 57: 139-142. https://doi.org/10.1007/BF00320154
- Kennedy MS, Yee GC, McGuire TR, et al., Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients. Transplantation. 1985; 40: 249- 253. https://doi.org/10.1097/00007890-198509000-00005
- Lindholm A, Ringden O, Lonnqvist B. The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients. Transplantation. 1987; 43: 680-684. https://doi.org/10.1097/00007890-198705000-00016
- Beal L, SL. NONMEM User Guide. 1992, San Francisco, CA: NONMEM Project Group, UCSF.
- Yee GC, McGuire TR, Gmur DJ, et al., Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation Influence of age, obesity, and hematocrit. Transplantation.1988; 46: 399-402. https://doi.org/10.1097/00007890-198809000-00012
- Schultz KR, Nevill TJ, Joze CL, et al., The pharmacokinetics of oral cyclosporin A (Neoral) during the first month after bone marrow transplantation. Transplant Proc. 1998; 30: 1668-1670. https://doi.org/10.1016/S0041-1345(98)00385-6
- Rui JZ, Zhuo HT, Jiang GH, et al., Evaluation of population pharmacokinetics of cyclosporin A in renal transplantation patients with NONMEM, Yao Xue Xue Bao. 1995; 30(4): 241-247.
- Shibata N, Hayakawa T, Hoshino N, et al., A predictive model for area under the concentration versus time curve of cyclosporin A using several routine monitoring results in renal transplant patients. Biol Pharm Bull. 1997; 20(8): 897-903. https://doi.org/10.1248/bpb.20.897
- Min DI, Lee M, Ku YM, et al., Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther 2000 Nov; 68(5): 478-486. https://doi.org/10.1067/mcp.2000.111255
- Molpeceres J, Chacon M, Guzman M, et al., Dependency of cyclosporine tissue distribution and metabolism on the age and gender of rats after a single intravenous dose. Int J Pharm. 2000 Mar 20; 197(1-2): 129-141. https://doi.org/10.1016/S0378-5173(99)00461-5
- Jacobson PA, Fuki NG, Kathlenn GE, et al., Posttansplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation. Biology of blood and marrow transplantation 2003: 9: 304-311. https://doi.org/10.1016/S1083-8791(03)00076-4
- Wu KH, Cui YM, Guo JF, et al., Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos. 2005; 33(9): 1268-1275. https://doi.org/10.1124/dmd.105.004358
- Charpiat, Bruno, Falconi, et al., A Population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with bayesian fitting. Ther Drug Monit. 1998; 20(2): 158-164. https://doi.org/10.1097/00007691-199804000-00005
- Rosenbaum SE, Baheti G, Trull AK, et al., Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit. 2005; 27(2): 116-122. https://doi.org/10.1097/01.ftd.0000148448.51225.2c
- Yee GC, Kennedy MS, Storb R, et al., Effect of hepatic dysfunction on oral cyclosporin pharmacokinetics in marrow transplant patients. Blood. 1984; 64: 1277-1279.
- Kahan BD, Kramer WG, Wideman C, et al., Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation. 1986; 41: 459-464. https://doi.org/10.1097/00007890-198604000-00009
- Moyer TP, Johnson P, Faynor SM, et al., Cyclosporine: A review of drug monitoring problems and presentation of a simple, accurate liquid chromatographic procedure that solves these problems. Clin Biochem. 1986; 19: 83-89. https://doi.org/10.1016/S0009-9120(86)80053-4
- Donatsch P, Abisch E, Homberger M, et al., A radioimmunoassay to measure cyclosporin A in plasma and serum samples. J Immunoassay. 1981; 2: 19-32. https://doi.org/10.1080/01971528108062989
- McLachlan AJ, Tett SE. Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach.Ther Drug Monit. 1998; 20: 390-395. https://doi.org/10.1097/00007691-199808000-00007
- Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part I). Clin Pharmacokinet. 1990; 19: 319-332. https://doi.org/10.2165/00003088-199019040-00004
- Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part II). Clin Pharmacokinet. 1990; 19: 400-415. https://doi.org/10.2165/00003088-199019050-00004
- Yates CR, Zhang W, Song P, et al., The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 2003; 43(6): 555-564. https://doi.org/10.1177/0091270003253617
- Pichard L, Fabre I, Fabre G, et al., Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos. 1990; 18(5): 595-606.
- Jones TE, Morris RG, Mathew TH. Diltiazem-cyclosporin pharmacokinetic interaction--dose-response relationship. Br J Clin Pharmacol. 1997; 44(5): 499-504.